Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002182712 | SCV002344858 | likely benign | RASopathy | 2023-09-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004603156 | SCV005098188 | likely benign | Cardiovascular phenotype | 2024-06-12 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Clinical Genomics Laboratory, |
RCV004820907 | SCV005441795 | uncertain significance | CBL-related disorder | 2022-08-08 | criteria provided, single submitter | clinical testing | The p.Ala678= variant in the CBL gene has not been previously reported in association with disease. This variant was absent from large population databases, including the Genome Aggregation Database (http://gnomad.broadinstitute.org/). This variant is present in ClinVar (Variation ID: 1549482). The p.Ala678= variant is a synonymous variant which is not expected to alter the CBL protein. Computational splicing tools do not agree on the predicted impact to splicing; however, the accuracy of in silico algorithms is limited. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, the significance of the p.Ala678= variant is uncertain. Additional information is needed to resolve the significance of this variant. [ACMG evidence codes used: PM2] |